患者人口统计学与燃烧的多发性骨髓瘤进展到多发性骨髓瘤之间的关联:A SEER-Medicare数据分析
Poy Theprungsirikul1, Rong Wang2, Ishfaq Ahmad3
1Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT.
Clinical lymphoma, myeloma & leukemia
|July 16, 2025
概括
年龄,而不是种族或性别,显著影响着烂的多发性骨髓瘤 (SMM) 进展到症状多发性骨髓瘤 (MM). 年龄较大与SMM进展风险较低有关.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 有限的风险分层模型用于将多发性骨髓瘤 (SMM) 转化为症状性多发性骨髓瘤 (MM) 的进展.
- 患者人口统计学 (如种族,性别和年龄) 对SMM进展的影响需要进一步调查.
研究的目的:
- 调查患者人口统计 (种族,性别,年龄) 与燃烧性多发性骨髓瘤 (SMM) 到症状性多发性骨髓瘤 (MM) 的进展之间的联系.
主要方法:
- 对2007-2019年的SEER-Medicare数据进行分析,以识别SMM患者.
- 利用考克斯的比例危险模型和引导来评估种族,性别,年龄和SMM进展之间的关联.
- 作为对照对非癌症医疗保险受益人进行调整.
主要成果:
- 在1235名SMM患者中,69.3%的患者进展为症状MM.
- 种族和性别与SMM进展没有显著的关联.
- 年龄的增加与SMM进展有负面关联,老年人群的风险降低.
结论:
- 年龄是SMM进展的重要因素,老年人患病风险较低.
- 种族和性别似乎不是SMM进展的重要预测因素.
- 这些发现为多发性骨髓瘤的自然历史建模提供了宝贵的见解.
更多相关视频
相关概念视频
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Comparing the Survival Analysis of Two or More Groups
292
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
292
Kaplan-Meier Approach
274
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
274


